Benefit of Gemcitabine/Nab-Paclitaxel Rescue of Patients with Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma after Early Failure of FOLFIRINOX

Timothy J. Vreeland, Florencia McAllister, Sanaz Javadi, Laura R. Prakash, David R. Fogelman, Linus Ho, Gauri Varadhachary, Thomas A. Aloia, Jean Nicolas Vauthey, Jeffrey E. Lee, Michael P. Kim, Matthew H.G. Katz, Ching Wei D. Tzeng

Research output: Contribution to journalArticlepeer-review

21 Scopus citations

Abstract

Neoadjuvant therapy (NT) is used for advanced pancreatic ductal adenocarcinoma (PDAC). No clear guidelines exist for switching therapies when patients do not respond to initial NT. We sought to characterize patients who underwent early switch from FOLFIRINOX to gemcitabine/nab-paclitaxel (GA) as NT for PDAC. Methods We identified patients at a single institution switched from FOLFIRINOX to GA within the first 4 months of NT for PDAC during 2012-2017. We compared clinicopathologic data and oncologic outcomes. Results Of 25 patients who met the criteria, 21 showed a serologic or radiographic response to GA; 11 (52%) reached resection. Responders had decreased carbohydrate antigen (CA) 19-9 levels from pretreatment to post-GA (P = 0.036). Resected responders had significantly decreased CA 19-9 comparing preswitch to post-GA (P = 0.048). The only predictor of GA response was prechemotherapy CA 19-9 of less than1000 U/mL (P = 0.021). Predictors of reaching resection were head/uncinate tumor (P = 0.010) and presenting stage lower than locally advanced (P = 0.041). Conclusions When patients do not respond to neoadjuvant FOLFIRINOX, early switch to GA should be considered. Future efforts should be directed toward identifying markers that will allow correct choice of initial therapy rather than attempting to rescue patients who respond poorly to first-line therapy.

Original languageEnglish (US)
Pages (from-to)837-843
Number of pages7
JournalPancreas
Volume48
Issue number6
DOIs
StatePublished - Jul 1 2019

Keywords

  • FOLFIRINOX
  • chemotherapy switch
  • gemcitabine-Abraxane
  • neoadjuvant therapy
  • pancreatic ductal adenocarcinoma

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Hepatology
  • Endocrinology

MD Anderson CCSG core facilities

  • Clinical Trials Office

Fingerprint

Dive into the research topics of 'Benefit of Gemcitabine/Nab-Paclitaxel Rescue of Patients with Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma after Early Failure of FOLFIRINOX'. Together they form a unique fingerprint.

Cite this